Navigation Links
Boston Scientific Announces Results for First Quarter Ended March 31, 2008
Date:4/21/2008

NATICK, Mass., April 21 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced financial results for the first quarter ended March 31, 2008, as well as guidance for net sales and earnings per share (EPS) for the second quarter of 2008.

First quarter highlights:

-- Achieved net sales of $2.046 billion and adjusted EPS of $0.24

-- Improved earnings through ongoing, stringent expense management

-- Maintained leading position in the worldwide drug-eluting stent (DES)

market

-- Received approval for six cardiac rhythm management (CRM) products

-- Grew Neuromodulation sales 40 percent

-- Increased Endosurgery sales nine percent

-- Completed the sale of five non-strategic businesses

"We continued to make good progress during the quarter, particularly in our efforts to bring expenses in line with revenues," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "Our earnings benefited from our ongoing expense management and were also helped by favorable tax items. Despite the arrival of a third DES competitor in the United States, we held our leadership positions in both the U.S. and worldwide markets. Our six CRM product approvals were exciting news, and they will contribute to our future growth in that market. The performance of our Neuromodulation group was impressive, and our Endosurgery group turned in another solid quarter. Our progress furthered our goals of restoring profitable sales growth, increasing shareholder value and strengthening Boston Scientific for the future."

Net sales for the first quarter of 2008 were $2.046 billion, including sales from divested businesses of $32 million, as compared to $2.086 bi (4%)

EMEA 507 469 8% (4%)

INTER-CONTINENTAL 390 313 25% 11%

INTERNATIONAL 897 782 15% 2%

DIVESTED BUSINESSES 32 135 N/A N/A

WORLDWIDE $2,046 $2,086 (2%) (7%)

Three Months Ended

March 31, Change

As Reported Constant

Currency Currency

In millions 2008 2007 Basis Basis

CARDIOVASCULAR $911 $923 (1%) (6%)

NEUROVASCULAR 92 90 2% (6%)

PERIPHERAL EMBOLIZATION 22 22 3% (4%)

NEUROVASCULAR 114 112 2% (6%)

CARDIAC RHYTHM MANAGEMENT 565 539 5% 0%

ELECTROPHYSIOLOGY 38 36 5% 2%

CARDIAC RHYTHM MANAGEMENT 603 575 5% 0%

ENDOSCOPY 229 206 11% 5%

UROLOGY 100 95 5% 2%

ENDOSURGERY 329 301 9% 4%

NEUROMODULATION 57 40 40% 40%

DIVESTED BUSINESSES 32 135 N/A N/A

WORLDWIDE $2,046 $2,086 (2%) (7%)

Growth rates are based on actual, non-rounded amounts.

BOSTON SCIENTIFIC CORPORATION

NON-GAAP CONSTANT CURRENCY NET SALES RECONCILIATIONS

(Unaudited)

Q1 2008 Net Sales as compared to Q1 2007

Change Estimated

As Reported Constant Impact of

Currency Currency Foreign

In millions Basis Basis Currency

DOMESTIC $(52) $(52) $-

EMEA 38 (17) 55

INTER-CONTINENTAL 77 35 42

INTERNATIONAL 115 18 97

DIVESTED BUSINESSES (103) (105) 2

WORLDWIDE $(40) $(139) $99

Q1 2008 Net Sales as compared to Q1 2007

Change Estimated

As Reported Constant Impact of

Currency Currency Foreign

In millions Basis Basis Currency

CARDIOVASCULAR $(12) $(59) $47

NEUROVASCULAR 2 (5) 7

PERIPHERAL EMBOLIZATION - (1) 1

NEUROVASCULAR 2 (6) 8

CARDIAC RHYTHM MANAGEMENT 26 1 25

ELECTROPHYSIOLOGY 2 1 1

CARDIAC RHYTHM MANAGEMENT 28 2 26

ENDOSCOPY 23 11 12

UROLOGY 5 2 3

ENDOSURGERY 28 13 15

NEUROMODULATION 17 16 1

DIVESTED BUSINESSES (103) (105) 2

WORLDWIDE $(40) $(139) $99

An explanation of the Company's use of these non-GAAP measures is provided

at the end of this document.

BOSTON SCIENTIFIC CORPORATION

ESTIMATED NON-GAAP NET INCOME PER SHARE RECONCILIATIONS

(Unaudited)

Q2 2008 Estimate Q2 2008 Estimate

(Low) (High)

GAAP results $0.04 $0.09

Estimated acquisition-related charges 0.01 0.01

Estimated restructuring-related charges 0.02 0.02

Estimated amortization expense 0.07 0.07

Adjusted results $0.14 $0.19

An explanation of the Company's use of these non-GAAP measures is provided

at the end of this document.

Use of Non-GAAP Financial Measures

To supplement Boston Scientific's condensed consolidated financial

statements presented on a GAAP basis; the Company discloses certain non-

GAAP measures that exclude certain amounts, including non-GAAP net income,

non-GAAP net income per diluted share, and regional and divisional revenue

growth rates that exclude the impact of foreign exchange. These non-GAAP

measures are not in accordance with, or an alternative for, generally

accepted accounting principles in the United States.

The GAAP measure most comparable to non-GAAP net income is GAAP net income

and the GAAP measure most comparable to non-GAAP net income per diluted

share is GAAP net income per diluted share. Reconciliations of each of

these non-GAAP financial measures to the corresponding GAAP measure are

included in the accompanying schedules.

To calculate regional and divisional revenue growth rates that exclude the

impact of foreign exchange, the Company converts actual current-period net

sales from local currency to U.S. dollars using constant foreign exchange

rates. The GAAP measure most comparable to this non-GAAP measure is growth

rate percentages based on GAAP revenue. A reconciliation of this non-GAAP

financial measure to the corresponding GAAP measure is included in the

accompanying schedules.

Use and Economic Substance of Non-GAAP Financial Measures Used by Boston

Scientific

Management uses these supplemental non-GAAP measures to evaluate

performance period over period, to analyze the underlying trends in the

Company's business, to assess its performance relative to its competitors,

and to establish operational goals and forecasts that are used in

allocating resources. In addition, management uses these non-GAAP measures

to further its understanding of the performance of the Company's operating

segments. The adjustments excluded from the Company's non-GAAP measures

are consistent with those excluded from its reportable segments' measure

of profit or loss. These adjustments are excluded from the segment

measures that are reported to the Company's chief operating decision maker

and are used to make operating decisions and assess performance.

The following is an explanation of each of the adjustments that management

excluded as part of its non-GAAP measures for the three month periods

ending March 31, 2008 and March 31, 2007 and for the forecasted three

month period ending June 30, 2008, as well as reasons for excluding each

of these individual items:

-- Acquisition-related charges -- These adjustments primarily consist of

purchased research and development, integration costs associated with

the Company's acquisition of Guidant, and a fair value adjustment

related to the sharing of proceeds feature of the Abbott stock

purchase. Purchased research and development is a highly variable

charge based on valuation assumptions. Management removes the impact of

purchased research and development from the Company's operating results

to assist in assessing the Company's operating performance and cash

generated from operations. The integration costs associated with the

Company's acquisition of Guidant do not reflect expected on-going

future operating expenses. The fair value adjustment related to the

sharing of proceeds feature of the Abbott stock purchase is a non-cash

adjustment and is not indicative of the Company's on-going operations.

Accordingly, management excluded these charges for purposes of

calculating these non-GAAP measures to facilitate an evaluation of the

Company's current operating performance and a comparison to the

Company's past operating performance.

-- Gain on divestitures -- These gains are not indicative of future

operating performance and are not used by management to assess

operating performance. Accordingly, management excluded these amounts

for purposes of calculating these non-GAAP measures to facilitate an

evaluation of the Company's current operating performance and a

comparison to the Company's past operating performance.

-- Restructuring-related charges -- These adjustments primarily represent

employee-related termination benefits, asset write-downs and other

costs associated with the Company's restructuring initiatives. These

expenses are not indicative of the Company's on-going operating

performance and are excluded by management in assessing the Company's

operating performance, and are also excluded from the Company's

operating segments' measures of profit and loss used for making

operating decisions and assessing performance. Accordingly, management

excluded these charges for purposes of calculating these non-GAAP

measures to facilitate an evaluation of the Company's current operating

performance and a comparison to the Company's past operating

performance.

-- Amortization expense -- Amortization expense is a non-cash charge and

does not impact the Company's liquidity or compliance with the

covenants included in its debt agreements. Following the Company's

acquisition of Guidant, and the related increase in the Company's debt,

management has heightened its focus on cash generation and debt pay

down. Management removes the impact of amortization from the Company's

operating performance to assist in assessing the Company's cash

generated from operations. Management believes this is a critical

metric for the Company in measuring the Company's ability to generate

cash and pay down debt. Therefore, amortization expense is excluded

from management's assessment of operating performance and is also

excluded from the measures management uses to set employee

compensation. Accordingly, management believes this may be useful

information to users of its financial statements and therefore has

excluded these charges for purposes of calculating these non-GAAP

measures to facilitate an evaluation of the Company's current operating

performance, particularly in terms of liquidity.

-- Foreign exchange on net sales -- The impact of foreign exchange is

highly variable and difficult to predict. Accordingly, management

excludes the impact of foreign exchange for purposes of reviewing

regional and divisional revenue growth rates to facilitate an

evaluation of the Company's current operating performance and

comparison to the Company's past operating performance.

Material Limitations Associated with the Use of Non-GAAP Financial

Measures

Non-GAAP net income, non-GAAP net income per diluted share, and regional

and divisional revenue growth rates that exclude the impact of foreign

exchange may have limitations as analytical tools, and these non-GAAP

measures should not be considered in isolation or as a replacement for

GAAP financial measures. Some of the limitations associated with the use

of these non-GAAP financial measures are:

-- Items such as purchased research and development, the gain on

divestitures, and the fair value adjustment related to the sharing of

proceeds feature of the Abbott stock purchase reflect economic costs to

the Company and are not reflected in non-GAAP net income and non-GAAP

net income per diluted share.

-- Items such as Guidant integration costs and restructuring-related

expenses that are excluded from non-GAAP net income and non-GAAP net

income per diluted share can have a material impact on cash flows and

GAAP net income and net income per diluted share.

-- Items such as amortization of purchased intangible assets, though not

directly affecting Boston Scientific's cash flow position, represent a

reduction in value of intangible assets over time. The expense

associated with this reduction in value is not included in Boston

Scientific's non-GAAP net income or non-GAAP net income per diluted

share and therefore these measures do not reflect the full economic

effect of the reduction in value of those intangible assets.

-- Revenue growth rates stated on a constant currency basis, by their

nature, exclude the impact of foreign exchange, which may have a

material impact on GAAP net sales.

-- Other companies may calculate non-GAAP net income, non-GAAP net income

per diluted share, or regional and divisional revenue growth rates that

exclude the impact of foreign exchange differently than Boston

Scientific does, limiting the usefulness of those measures for

comparative purposes.

Compensation for Limitations Associated with Use of Non-GAAP Financial

Measures

Boston Scientific compensates for the limitations on its non-GAAP

financial measures by relying upon its GAAP results to gain a complete

picture of the Company's performance. The non-GAAP numbers focus instead

upon the core business of the Company, which is only a subset, albeit a

critical one, of the Company's performance.

The Company provides detailed reconciliations of each non-GAAP financial

measure to its most directly comparable GAAP measure in the accompanying

schedules, and Boston Scientific encourages investors to review these

reconciliations.

Usefulness of Non-GAAP Financial Measures to Investors

The Company believes that presenting non-GAAP net income, non-GAAP net

income per share, and regional and divisional revenue growth rates that

exclude the impact of foreign exchange in addition to the related GAAP

measures provides investors greater transparency to the information used

by Boston Scientific management for its financial and operational

decision-making and allows investors to see Boston Scientific's results

"through the eyes" of management. The Company further believes that

providing this information better enables Boston Scientific's investors to

understand the Company's operating performance and to evaluate the

methodology used by management to evaluate and measure such performance.

llion for the first quarter of 2007, including sales from divested businesses of $135 million.

Worldwide sales of the Company's drug-eluting coronary stent systems for the first quarter of 2008 were $428 million, as compared to $468 million for the first quarter of 2007. U.S. sales of these systems were $218 million, as compared to $293 million. International sales of these systems were $210 million, as compared to $175 million. Worldwide sales of coronary stent systems were $490 million, as compared to $527 million. U.S. sales of these systems were $244 million, as compared to $317 million. International sales of these systems were $246 million, as compared to $210 million.

Worldwide sales of the Company's CRM products for the first quarter of 2008 were $565 million, which included $411 million of implantable cardioverter defibrillator (ICD) sales, as compared to worldwide CRM sales of $539 million for the first quarter of 2007, which included $398 million of ICD sales. U.S. CRM product sales were $356 million, which included $274 million of ICD sales, as compared to $349 million, which included $273 million of ICD sales. International CRM sales were $209 million, which included $137 million of ICD sales, as compared to $190 million, which included $125 million of ICD sales.

Reported net income for the first quarter of 2008 was $322 million, or $0.21 per share. Reported results included net charges (after-tax) of $35 million, or approximately $0.03 per share, for acquisition and restructuring-related charges and amortization expense, net of divestiture-related gains, which consisted of the following:

-- $250 million gain (pre-tax), $114 million (after-tax), associated with

the sale of five non-strategic businesses;

-- $13 million of purchased research and development (pre-tax), $8 million

(after-tax);

-- $44 million of charges (pre-tax), $32 million (after-tax), associated

with the Company's expense and head count reduction initiatives; and

-- $143 million of amortization expense (pre-tax), $109 million

(after-tax).

Adjusted net income for the quarter, excluding these amounts, was $357 million, or $0.24 per share. Included in reported and adjusted net income was $43 million, or $0.03 per share, of favorable discrete income tax items, and $8 million of income, or $0.01 per share, associated with divested businesses.

Reported net income for the first quarter of 2007 was $120 million, or $0.08 per share. Reported results for the first quarter of 2007 included charges associated with the Company's 2006 acquisition of Guidant Corporation and amortization expense (pre-tax) of $180 million, or approximately $0.09 per share. Adjusted net income for the first quarter of 2007, excluding these charges and amortization expense, was $262 million, or $0.17 per share.

Guidance for Second Quarter 2008

The Company estimates net sales for the second quarter of 2008 of between $1.950 billion and $2.075 billion. Adjusted net income, excluding acquisition, divestiture, litigation and restructuring-related charges, and amortization expense, is estimated to range between $0.14 and $0.19 per share. The Company estimates reported net income on a GAAP basis of between $0.04 and $0.09 per share.

Boston Scientific management will be discussing these results with analysts on a conference call at 8:30 a.m. (ET) Tuesday, April 22, 2008. The Company will webcast the call to all interested parties through its website: http://www.bostonscientific.com. Please see the website for details on how to access the webcast. The webcast will be available for one year on the Boston Scientific website.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our financial performance, our programs to increase shareholder value, new product approvals, business divestitures, our growth strategy, market recovery and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item IA- Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file thereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.

Use of non-GAAP Financial Information

A reconciliation of the Company's non-GAAP financial measures to the corresponding GAAP measures, and an explanation of the Company's use of these non-GAAP measures, is included in the exhibits attached to this press release.

CONTACT:

Paul Donovan

508-650-8541 (office)

508-667-5165 (mobile)

Media Relations

Boston Scientific Corporation

Larry Neumann

508-650-8696 (office)

Investor Relations

Boston Scientific Corporation

BOSTON SCIENTIFIC CORPORATION

CONDENSED CONSOLIDATED GAAP RESULTS OF OPERATIONS

(Unaudited)

Three Months Ended

March 31,

In millions, except per share data 2008 2007

Net sales $2,046 $2,086

Cost of products sold 580 568

Gross profit 1,466 1,518

Operating expenses

Selling, general and administrative expenses 661 735

Research and development expenses 244 289

Royalty expense 46 52

Amortization expense 143 155

Purchased research and development 13 5

Restructuring charges 29

Gain on divestitures (250)

886 1,236

Operating income 580 282

Other income (expense):

Interest expense (131) (141)

Other, net 13 18

Income before income taxes 462 159

Income tax expense 140 39

Net income $322 $120

Net income per common share -

assuming dilution $0.21 $0.08

Weighted average shares outstanding -

assuming dilution 1,500.1 1,497.8

BOSTON SCIENTIFIC CORPORATION

NON-GAAP NET INCOME AND NET INCOME PER COMMON SHARE RECONCILIATIONS

(Unaudited)

Three Months Three Months

Ended Ended

March 31, 2008 March 31, 2007

Impact Impact

per per

Net diluted Net diluted

In millions, except per share data income share income share

GAAP results $322 $0.21 $120 $0.08

Non-GAAP adjustments:

Acquisition-related charges 8 0.01 20 0.01

Gain on divestitures (114) (0.08)

Restructuring-related charges 32 0.02

Amortization expense 109 0.08 122 0.08

Adjusted results $357 $0.24 $262 $0.17

An explanation of the Company's use of these non-GAAP measures is provided

at the end of this document.

BOSTON SCIENTIFIC CORPORATION
NON-GAAP NET INCOME AND NET INCOME PER COMMON SHARE RECONCILIATIONS (CONT.)
(Unaudited)

Three Months Ended

March 31,

2008 2007

Acquisition-related charges:

Purchased research and development $13 $5

Integration costs (a) 12

Fair-value adjustment for the sharing of

proceeds feature of the Abbott

Laboratories stock purchase (b) 8

13 25

Income tax benefit (d) (5) (5)

Acquisition-related charges, net of tax $8 $20

Gain on divestitures:

Gain on divestitures $(250)

Income tax expense (d) 136

Gain on divestitures, net of tax $(114)

Restructuring-related charges:

Restructuring-related charges (c) $44

Income tax benefit (d) (12)

Restructuring-related charges, net of tax $32

Amortization expense:

Amortization expense $143 $155

Income tax benefit (d) (34) (33)

Amortization expense, net of tax $109 $122

(a) Recorded expenses of $9 million to selling, general and administrative

expenses, $2 million to cost of products sold, and $1 million to

research and development expenses.

(b) Recorded to other, net.

(c) Recorded $29 million to restructuring charges, $9 million to selling,

general and administrative expenses, $4 million to cost of products

sold, and $2 million to research and development expenses.

(d) Amounts are tax effected at the Company's effective tax rate, unless

the amount is a significant unusual or infrequently occurring item in

accordance with FASB Interpretation No. 18, "Accounting for Income

Taxes in Interim Periods."

BOSTON SCIENTIFIC CORPORATION

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

March 31, December 31,

In millions 2008 2007

Assets

Current assets:

Cash and cash equivalents $1,739 $1,452

Trade accounts receivable, net 1,496 1,502

Inventories 781 725

Deferred income taxes 873 679

Assets held for sale 1,099

Other current assets 352 464

Total current assets 5,241 5,921

Property, plant and equipment, net 1,736 1,735

Investments 321 317

Other assets 143 157

Intangible assets, net 22,905 23,067

$30,346 $31,197

Liabilities and Stockholders' Equity

Current liabilities:

Borrowings due within one year $257 $256

Accounts payable and accrued expenses 2,422 2,680

Liabilities associated with assets

held for sale 39

Other current liabilities 714 275

Total current liabilities 3,393 3,250

Long-term debt 7,311 7,933

Deferred income taxes 2,230 2,284

Other long-term liabilities 2,021 2,633

Stockholders' equity 15,391 15,097

$30,346 $31,197

BOSTON SCIENTIFIC CORPORATION

WORLDWIDE SALES

(Unaudited)

Three Months Ended

March 31, Change

As Reported Constant

Currency Currency

In millions 2008 2007 Basis Basis

DOMESTIC $1,117 $1,169 (4%)
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan
4. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
5. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
6. Boston Scientific Announces Election of Ray Elliott to Its Board of Directors
7. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
8. Boston Scientific Releases Remote Monitoring Data from its Wireless LATITUDE(R) Patient Management System
9. Genzyme Begins Major Expansion of Boston Manufacturing Facility
10. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
11. Boston Scientific to Webcast Conference Call Discussing Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... BOSTON , June 27, 2016   Ginkgo ... biology to industrial engineering, was today awarded as ... a selection of the world,s most innovative companies. ... at scale for the real world in the ... organism engineers work directly with customers including Fortune ...
(Date:6/24/2016)... ... ... While the majority of commercial spectrophotometers and fluorometers use the z-dimension of 8.5 ... end machines that use the more unconventional z-dimension of 20mm. Z-dimension or ... the cuvette holder. , FireflySci has developed several Agilent flow cell product lines ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
(Date:6/23/2016)... 23, 2016 A person commits a crime, and ... to track the criminal down. An outbreak of ... Drug Administration (FDA) uses DNA evidence to track down the ... Sound far-fetched? It,s not. The FDA has increasingly used a ... of foodborne illnesses. Put as simply as possible, whole genome ...
Breaking Biology Technology:
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange is ... users of its soon to be launched online site ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders ... of DNA technology to an industry that is notorious ...
(Date:3/22/2016)... , March 22, 2016 ... research report "Electronic Sensors Market for Consumer Industry by ... & Others), Application (Communication & IT, Entertainment, ... - Global Forecast to 2022", published by ... is expected to reach USD 26.76 Billion ...
Breaking Biology News(10 mins):